Open access · CC-BY
via OpenAlex
Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
Rachel M. Williamson, Jackie F. Price, Stephen Glancy, Elisa Perry, Lisa D. Nee, Peter Clive Hayes, Brian M. Frier, Liesbeth A.F. Van Look, Geoffrey I. Johnston, Rebecca M. Reynolds, Mark W. J. Strachan, on behalf of the Edinburgh Type 2 Diabetes Study Investigators
Diabetes Care · 2011 · ▲ 391 citations
Abstract
OBJECTIVE: Type 2 diabetes is an established risk factor for development of hepatic steatosis and nonalcoholic fatty liver disease (NAFLD). We aimed to determine the prevalence and clinical correlates of these conditions in a large cohort of people with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 939 participants, aged 61-76 years, from the Edinburgh Type 2 Diabetes Study (ET2DS)-a large, randomly selected population of people with type 2 diabetes-underwent liver ultrasonography. Ultrasound gradings of steatosis were compared with magnetic resonance spectroscopy in a subgroup. NAFLD was defined as hepatic steatosis in the absence of a secondary cause (screened by questionnaire assessing alcohol and hepatotoxic medication use, plasma hepatitis serology, autoantibodies and ferritin, and record linkage to determine prior diagnoses of liver disease). Binary logistic regression was used to analyze independent associations of characteristics with NAFLD. RESULTS: Hepatic steatosis was present in 56.9% of participants. After excluding those with a secondary cause for steatosis, the prevalence of NAFLD in the study population was 42.6%. Independent predictors of NAFLD were BMI, lesser duration of diabetes, HbA(1c), triglycerides, and metformin use. These remained unchanged after exclusion of participants with evidence of hepatic fibrosis from the group with no hepatic steatosis. CONCLUSIONS: Prevalences of hepatic steatosis and NAFLD were high in this unselected population of older people with type 2 diabetes, but lower than in studies in which ultrasound gradings were not compared with a gold standard. Associations with features of the metabolic syndrome could be used to target screening for this condition.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2337/dc10-2229
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
Williamson, R.M., Price, J.F., Glancy, S., Perry, E., Nee, L.D., Hayes, P.C., Frier, B.M., Look, L.A.V., Johnston, G.I., Reynolds, R.M., Strachan, M.W.J., & Investigators, O.B.O.T.E.T.2.D.S. (2011). Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study. <em>Diabetes Care</em>. https://doi.org/10.2337/dc10-2229
Vancouver
Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011. doi:10.2337/dc10-2229.
BibTeX
@article{rachel2011Preval,
title = {Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study},
author = {Rachel M. Williamson and Jackie F. Price and Stephen Glancy and Elisa Perry and Lisa D. Nee and Peter Clive Hayes and Brian M. Frier and Liesbeth A.F. Van Look and Geoffrey I. Johnston and Rebecca M. Reynolds and Mark W. J. Strachan and on behalf of the Edinburgh Type 2 Diabetes Study Investigators},
journal = {Diabetes Care},
year = {2011},
doi = {10.2337/dc10-2229},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
AIDS 2020
Preprint · CC-BY
Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV
Työväentutkimus Vuosikirja 2008
Open access · OA
LIVER FAT IN THE METABOLIC SYNDROME AND TYPE 2 DIABETES
Diabetes Care 2022
Open access · OA
Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort
Clinical and experimental medicine 2026
Open access · OA
Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions.
Metabolites 2021
Open access · CC-BY
Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease
2022
Open access · CC-BY